Thus, thechallenges mentioned emphasize the necessity of new delivery systems and formulationstrategies
all of these clinical issues connect to issues w/ traditional drug development
Thus, thechallenges mentioned emphasize the necessity of new delivery systems and formulationstrategies
all of these clinical issues connect to issues w/ traditional drug development
Consequently, additional modifications (e.g., cyclization, DAAs) are oftenrequired, making the screening process more time-consuming and the manufacturingprocess more costly and complex
Yeah, I remember this. takes so mych longer than you would intitially expect
ESKAPE pathogens
Didn't know about C.auris that was new info to me
Antimicrobial resistance (AMR)
Using AI to combat it is so cool!
From a biochemical perspective, the plasma membrane controlsfluidity, permeability and possesses the ability to respond to stress
basic membrane functions
In the case of biofilms, QS is important for biofilm formation andcommunication or coordination within the biofilm
QS can dictate which EPS components are excreted and what gene expression is up/down regulated to maintain biofilm
Another mechanism of resistance against AMPs is biofilm formation, which is acommon virulence factor from ESKAPE pathogens
biofilms would prevent AMPs from accessing the membrane
antimicrobialactivity emerges not only from amino acid composition but also from structural elementssuch as secondary structure, amphipathicity, solvent accessibility and conformational stabil-ity
a variety of interacting factors impact antimicrobial capabilities
toxicity toward mammalian cells, poor serum stability, limited bioavailability
familiar/can explain this in the context of traditional drug development; translational barriers are significanrt